Pfizer Corporation

Abbvie Inc.

Monsanto Technology LLC

Lisa Maria Olson

Mark G Obukowicz

Paul Vincent Rucker

Kevin D Jerome

Xiao Hu

Ronald Keith Webber

Rajesh Devraj

Hengmiao Cheng

Hengmiao (Henry) Cheng

Gary A Decresenzo

Tariq Ghayur

Chengbin Wu

Peer Jacobson

Rajesh Vasant Kamath

Margaret Hugunin

Hamish John Allen

Carolyn A Cuff

Peter C Isakson

Julie Lindemann

Susan L Green

Ayman Kabakibi

Sreeinvasarao Vepachedu

Mark Obukowicz

Susan Hummert

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-&#x3b2;-hydroxysteroid dehydrogenase Type 1 enzyme.

11-&#x3b2;-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD1) inhibitors and uses thereof

The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.

Tricyclic compounds, compositions, and methods

Tricyclic compounds, compositions and methods

Tricyclic compound, compositions, and methods

Cancer in a mammal can be treated or prevented by administering to a mammal in need thereof a cancer inhibiting amount of metabolite(s) of &agr;-linolenic acid, such as stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosaptentaenic acid (22:5 n-3) and mixtures thereof, especially metabolites including stearidonic acid.

Use of &agr;-linolenic acid metabolites for treatment or prevention of cancer

Growing community of inventors

Hopkinton, MA, United States of America

Lisa Maria Olson